This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through September 7, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechnology: Archive
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
by Zacks Equity Research
ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.
ARGXPositive Net Change ALNYPositive Net Change AMRNPositive Net Change ALDXNegative Net Change
biotechnology
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
by Zacks Equity Research
Editas Medicine gains approval to launch the first-in-human phase I/II study of EDIT-401 in Australia, targeting LDL cholesterol through gene editing.
EDITPositive Net Change ALNYPositive Net Change AMRNPositive Net Change ALDXNegative Net Change
biotechnology
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
by Zacks Equity Research
VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.
VTRSPositive Net Change ALNYPositive Net Change PCRXNegative Net Change AMRNPositive Net Change
biotechnology biotechs medical pharmaceuticals
4 CNS Drug Stocks Worth Watching This World Mental Health Day
by Ahan Chakraborty
AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
ALKSPositive Net Change NBIXPositive Net Change ACADPositive Net Change AXSMNegative Net Change
biotechnology biotechs medical pharmaceuticals
Roche Gets FDA Approval for Another Label Expansion of Tecentriq
by Zacks Equity Research
Roche wins FDA approval for Tecentriq in stage III dMMR colon cancer, with trial data showing a 50% lower risk of recurrence or death.
RHHBYPositive Net Change PFEPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
by Zacks Equity Research
argenx shares tumble 12% after discontinuing its late-stage Sjogren's disease study, while positive FB102 data in celiac disease offer a contrasting pipeline development.
ARGXPositive Net Change ALNYPositive Net Change CRSPPositive Net Change
biotechnology biotechs medical pharmaceuticals
New Strong Sell Stocks for October 9th
by Zacks Equity Research
ACH, ARDX and DPRO have been added to the Zacks Rank #5 (Strong Sell) List on October 9th, 2026.
ACHNegative Net Change ARDXPositive Net Change DPRONegative Net Change
biotechnology
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
by Zacks Equity Research
Novartis wins FDA approval for Rhapsido in symptomatic dermographism, expanding its chronic hives opportunity as pipeline setbacks raise pressure for growth.
NVSPositive Net Change PFEPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Here's Why You Should Add LPCN Stock to Your Portfolio Now
by Zacks Equity Research
Lipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.
LPCNNegative Net Change ALNYPositive Net Change AMRNPositive Net Change ALDXNegative Net Change
biotechnology
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
by Zacks Equity Research
RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.
RAREPositive Net Change ALNYPositive Net Change ALDXNegative Net Change CRSPPositive Net Change
biotechnology biotechs medical pharmaceuticals